6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Combined treatment with pegylated interferon (PEG-IFN) and ribavirin is currently recommended for the treatment of chronic hepatitis C virus (HCV) infection. Many side effects including hair disorders have, however, been reported related to this treatment. Alopecia universalis is a severe form of hair disorder. Three cases of alopecia universalis during PEG-IFN and ribavirin combination therapy have been reported in the literature. Herein is reported a case of reversible alopecia universalis, with complete hair loss extending to the whole body, secondary to PEG-IFN alpha-2b and ribavirin combination therapy for chronic HCV infection. Hair regrowth began within 3 months of the completion of combined therapy. In case the liver disease is advanced, and virologic response occurs, treatment can still be completed, as it appears that these side effects are reversible.

          Related collections

          Author and article information

          Journal
          Eur J Gastroenterol Hepatol
          European journal of gastroenterology & hepatology
          Ovid Technologies (Wolters Kluwer Health)
          0954-691X
          0954-691X
          Sep 2007
          : 19
          : 9
          Affiliations
          [1 ] Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey. edoyuk@ogu.edu.tr
          Article
          00042737-200709000-00015
          10.1097/MEG.0b013e32818b27e5
          17700271
          18d97f50-a103-4518-8693-6d215ef2c0bf
          History

          Comments

          Comment on this article